Pharming Group N.V. (FRA:PHGN)
Germany · Delayed Price · Currency is EUR | Market Cap | 716.27M -8.0% |
| Revenue (ttm) | 320.78M +7.8% |
| Net Income | 8.14M |
| EPS | 0.01 |
| Shares Out | n/a |
| PE Ratio | 84.32 |
| Forward PE | 31.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 275 |
| Open | 0.9340 |
| Previous Close | 0.8916 |
| Day's Range | 0.9340 - 0.9340 |
| 52-Week Range | 0.8194 - 1.7620 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kδ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev... [Read more]
News
Pharming (PHAR) Lowers 2026 Expense Forecast Amid Promising Clinical Trial Updates
Pharming (PHAR) Lowers 2026 Expense Forecast Amid Promising Clinical Trial Updates
Pharming Group (PHAR) Reports 21% Revenue Growth Led by RUCONEST and Joenja
Pharming Group (PHAR) Reports 21% Revenue Growth Led by RUCONEST and Joenja
Pharming narrows FY26 revenue view to $380M-$390M from $375M-$395M
Consensus $383.35M. Cuts FY26 operating expense view to $310M-$315M from $315M-$320M. The company said, “At ESID 2026, Pharming (PHAR) presented positive Phase II data for leniolisib in patients with ...
Pharming Group (PHAR) Reports Q3 Revenue Growth, Revises 2026 Guidance
Pharming Group (PHAR) Reports Q3 Revenue Growth, Revises 2026 Guidance
Pharming Group Q3 Prel. Revenue Rises; Tightens FY26 Revenue Guidance
(RTTNews) - Pharming Group N.V. (PHGUF.PK, PHGUF.OB, PHAR, PHARM.AS), a Netherlands-based biotechnology company focused on rare immune and genetic diseases, on Thursday reported increased preliminary ...
Pharming Group N.V.: Pharming Group announces third quarter 2026 revenues above market expectations
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in l...
Pharming Group announces third quarter 2026 revenues above market expectations
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025 Third quarter 2026 total operating expenses of approximately US$74.6 million, in lin...
Pharming Group Earnings release: Q3 2026
Pharming Group released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
Pharming's Leniolisib Shows Promise Beyond APDS In Rare Genetic Immune Disorders
(RTTNews) - Pharming Group N.V. (PHAR) reported positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies associated wit...
Pharming Reports Positive Phase II Data For Leniolisib In Rare Genetic Immune Disorders
(RTTNews) - On Wednesday, Pharming Group N.V. (PHAR) announced positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies...
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation Leniolisib was well-tolerate...
Pharming (PHAR) CEO Departure and Interim Leadership Amid Modest Undervaluation
Pharming (PHAR) CEO Departure and Interim Leadership Amid Modest Undervaluation
Pharming announces CEO Fabrice Chouraqui to step down
Pharming (PHAR) announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Chouraqui will step down as CEO and Executive Director, with immediate effect. To ensure continuit...
Pharming announces CEO transition
Leiden, the Netherlands, September 29, 2026 : Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Bo...
FDA Accepts Pharming's SNDA For Lower-Dose Joenja In Children With APDS
(RTTNews) - Pharming Group N.V. (PHAR) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval of lower doses of Joenja (l...
Pharming announces FDA acceptance, Priority review of sNDA for Joenja
Pharming (PHAR) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application seeking approval for lower doses of Joenja, an oral, selective phosphoinositide ...
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
If approved, J oenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval of Joenja for children aged 4 to 11 years with AP...
Pharming’s initial Phase 2 Leniolisib data ‘encouraging,’ says H.C. Wainwright
Initial Phase 2 data for Pharming’s (PHAR) Leniolisib in genetically defined PIDs beyond APDS are encouraging, showing improvements in lymphoproliferative measures without new safety signals, with add...
Pharming announces ‘positive’ Phase 2 topline data for leniolisib in PIDs
Pharming (PHAR) announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies with immune dy...
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report...
Pharming Group Slides: Investor presentation
Pharming Group has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg Newly approved Joenja doses are e...
Pharming Group to participate in September investor conferences
Pharming Group to participate in investor conferences Sep. 14-15. H.C. Wainwright Growth Conference and Morgan Stanley Healthcare Conference in New York.
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Leiden, the Netherlands, August 13, 2026: Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patient...
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session.